Skip to content
2000
Volume 12, Issue 9
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Concurrent infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients positive for human immunodeficiency virus (HIV) is relatively common. The treatment of co-infected individuals is rather complex because the anti-viral therapy may be associated with drug-resistance, hepatotoxicity and lack of response. Herein, we present a summary of the available compounds and the recent recommendations concerning the therapeutic management of HIV/HBV and HIV/HCV co-infections.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955712800959062
2012-08-01
2025-01-14
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955712800959062
Loading

  • Article Type:
    Research Article
Keyword(s): adefovir; co-infection; drugs; entecavir; HBV; HCV; hepatitis B; hepatocellular carcinoma; HIV; lamivudine; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test